AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21360250 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with (99m)Technetium-nanocolloid and patent blue.
Number of subjects: 24
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk powder extracts
Number of subjects: 53
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk powder
Number of subjects: 53
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-casein
Number of subjects: 53
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-casein
Number of subjects: 53
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 53
Study 21361910 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-reactive IAA
Number of subjects: 53
Study 21362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche high-sensitive cTnT (hs-cTnT)
Number of subjects: 406
Study 21362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens cTnI-Ultra
Number of subjects: 406
Study 21362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott-Architect cTnI
Number of subjects: 406
Study 21362702 — intervention group
Group type: COMPARATOR
Intervention: Standard assay (Roche cTnT)
Number of subjects: 406
Study 21362702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive cTn assays
Number of subjects: 406
Study 21366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (1-year duration)
Number of subjects: 1118
Study 21366812 — intervention group
Group type: EXPERIMENTAL
Intervention: G-allele of rs10830963
Number of subjects: 1118
Study 21366812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1118
Study 21367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct water deprivation test (WDT) with copeptin measurement
Number of subjects: 70
Study 21367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct water deprivation test (WDT) with AVP measurement
Number of subjects: 70
Study 21367924 — intervention group
Group type: COMPARATOR
Intervention: Indirect water deprivation test (WDT)
Number of subjects: 70
Study 21367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline copeptin values greater than 20 pmol/liter
Number of subjects: 70
Study 21367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline copeptin values below 2.6 pmol/liter
Number of subjects: 70
Study 21367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ copeptin ratio (0800 to 1600 h) to serum sodium concentration at 1600 h
Number of subjects: 70
Study 21367942 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations <4.0 mEq/L
Number of subjects: 12209
Study 21367942 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations 4.0-4.4 mEq/L
Number of subjects: 12209
Study 21367942 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium concentrations 4.5-4.9 mEq/L
Number of subjects: 12209
Study 21368592 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 0
Study 21368592 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21368772 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 994
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1133
Study 21369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1133
Study 21371308 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal plasma treatment with a granulocyte bioreactor, treated twice within 72 hours for a mean of 342 ± 64 minutes/treatment with 1.41 ± 0.43 × 10E10 granulocytes from healthy donors.
Number of subjects: 10
Study 21371308 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal plasma treatment with a granulocyte bioreactor
Number of subjects: 10
Study 21372112 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO) 2500 orally every 2 weeks for 3 months
Number of subjects: 5
Study 21372112 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Number of subjects: 5
Study 21372155 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative prognostic risk score (IPRS)
Number of subjects: 406
Study 21372155 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients with related donors
Number of subjects: 406
Study 21372155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk group patients with related donors
Number of subjects: 406
Study 21372155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group patients
Number of subjects: 406
Study 21372167 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 9
Study 21372218 — intervention group
Group type: EXPERIMENTAL
Intervention: E7080 13 mg bid
Number of subjects: 27
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day simvastatin
Number of subjects: 125
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin
Number of subjects: 125
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin
Number of subjects: 125
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin (48 hours after admission)
Number of subjects: 125
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin treatment
Number of subjects: 125
Study 21372302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher statin doses
Number of subjects: 125
Study 21372613 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313 in males
Number of subjects: 889
Study 21372613 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313 in females
Number of subjects: 889
Study 21372613 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk allele rs17782313
Number of subjects: 889
Study 21372613 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight and lean controls
Number of subjects: 889
Study 21375584 — intervention group
Group type: EXPERIMENTAL
Intervention: SPINK-1/N34S mutation
Number of subjects: 239
Study 21375584 — intervention group
Group type: COMPARATOR
Intervention: Control group (without SPINK-1/N34S mutation)
Number of subjects: 239
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS with migraine without aura (CFS+MO)
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS with migraine with aura (CFS+MA)
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS with tension headaches only
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS with no headaches
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS with co-morbid tension and migraine headaches
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS+MA
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS+MO
Number of subjects: 203
Study 21375763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 203
Study 21375763 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 203
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive tests for fibrosis
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe fibrosis diagnosis
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness and FibroTest values
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness
Number of subjects: 1457
Study 21376047 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest results
Number of subjects: 1457
Study 21376093 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise session
Number of subjects: 14
Study 21376093 — intervention group
Group type: COMPARATOR
Intervention: Sedentary session
Number of subjects: 14
Study 21376417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 58
Study 21376417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 58
Study 21376417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide and Acarbose
Number of subjects: 58
Study 21377509 — intervention group
Group type: EXPERIMENTAL
Intervention: H6N1 influenza virus vaccine (10^7 TCID(50), 2 doses)
Number of subjects: 22
Study 21377509 — intervention group
Group type: EXPERIMENTAL
Intervention: H6N1 influenza virus vaccine (2 doses)
Number of subjects: 22
Study 21377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 13.3 mg/m(2)/day on days 1, 8, and 15 of each 28-day cycle (phase II component)
Number of subjects: 43
Study 21377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 17.7 mg/m(2)/d (phase I component)
Number of subjects: 43
Study 21377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin at a dosage of 13.3 mg/m(2)/d (phase I component)
Number of subjects: 43
Study 21378375 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 0
Study 21378375 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 0
Study 21378375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21380781 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex combined with CEF chemotherapy
Number of subjects: 119
Study 21381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Edinburgh Postnatal Depression Scale (EPDS≥10) indicating postpartum depression risk
Number of subjects: 9339
Study 21381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation (SI) as measured by item 10 of the EPDS
Number of subjects: 9339
Study 21381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonality in postpartum depression risk
Number of subjects: 9339
Study 21381158 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonality in suicidal ideation
Number of subjects: 9339
Study 21381892 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 300 μg weekly
Number of subjects: 44
Study 21382172 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose)
Number of subjects: 84
Study 21382172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 84
Study 21382172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (Clopidogrel and Aspirin)
Number of subjects: 84
Study 21382172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ST)
Number of subjects: 84
Study 21383241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (CP-690,550)
Number of subjects: 0
Study 21383282 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum free light chains (FLC)
Number of subjects: 295
Study 21383282 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal κ:λ FLC ratio
Number of subjects: 295
Study 21383282 — intervention group
Group type: COMPARATOR
Intervention: Normal serum free light chains (FLC)
Number of subjects: 295
Study 21383285 — intervention group
Group type: EXPERIMENTAL
Intervention: ARQ 197 at 100 to 400 mg twice per day
Number of subjects: 51
Study 21383285 — intervention group
Group type: EXPERIMENTAL
Intervention: ARQ 197
Number of subjects: 51
Study 21383338 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg)
Number of subjects: 18
Study 21384515 — intervention group
Group type: EXPERIMENTAL
Intervention: Flush blood from liver grafts
Number of subjects: 17
Study 21384515 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamines used to maintain mean arterial pressure
Number of subjects: 17
Study 21384515 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β, IL-2, IL-8 levels in flush blood
Number of subjects: 17
Study 21386092 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/od
Number of subjects: 20
Study 21386092 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/bid
Number of subjects: 20
Study 21386092 — intervention group
Group type: EXPERIMENTAL
Intervention: 162 mg/bid
Number of subjects: 20
Study 21386092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin dosing regimens
Number of subjects: 20
Study 21386111 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI protocol with a 32 item ordinal scale evaluating abnormalities in the basal ganglia and posterior fossa.
Number of subjects: 760
Study 21386974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg per day)
Number of subjects: 29133
Study 21386997 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 globular domain HA1(1-330) and HA0(1-500) proteins
Number of subjects: 2
Study 21386997 — intervention group
Group type: COMPARATOR
Intervention: H5N1 inactivated sub-virion vaccine
Number of subjects: 2
Study 21387287 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 16
Study 21387287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21388308 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial lung abnormalities present
Number of subjects: 2416
Study 21388319 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis
Number of subjects: 0
Study 21388319 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 0
Study 21388310 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily
Number of subjects: 9016
Study 21388310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9016
Study 21388447 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic signs (heart rate, cQT-interval, atrial fibrillation/flutter, left axis deviation, right and left bundle branch block)
Number of subjects: 5231
Study 21389182 — intervention group
Group type: EXPERIMENTAL
Intervention: G/G genotype with low saturated fatty acid (SFA) concentrations (below the median)
Number of subjects: 452
Study 21389182 — intervention group
Group type: EXPERIMENTAL
Intervention: G/G genotype with high saturated fatty acid (SFA) concentrations (above the median)
Number of subjects: 452
Study 21389182 — intervention group
Group type: COMPARATOR
Intervention: Minor A allele (G/A and A/A) with high saturated fatty acid (SFA) concentrations
Number of subjects: 452
Study 21389182 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPN10 rs2953171 SNP
Number of subjects: 452
Study 21391024 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician ratings of treatment improvement
Number of subjects: 101
Study 21391024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded laboratory rater reports
Number of subjects: 101
Study 21391024 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child pre-post reports of social anxiety symptoms
Number of subjects: 101
Study 21391405 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical caregivers (spouse, children)
Number of subjects: 1476
Study 21391405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical caregivers (in-law, sibling, nephew/niece, grandchild)
Number of subjects: 1476
Study 21391405 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving experience
Number of subjects: 1476
Study 21393027 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans analyzed using the threshold technique (%<-950HU) and low attenuation cluster analysis
Number of subjects: 1972
Study 21393027 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans scored as showing regions of gas trapping
Number of subjects: 1972
Study 21393027 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimates of emphysema
Number of subjects: 1972
Study 21393027 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis of low attenuation cluster size
Number of subjects: 1972
Study 21393326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells expanded using human serum
Number of subjects: 18
Study 21393329 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox monotherapy (30-40 mg/kg/day) for 18 months
Number of subjects: 0
Study 21393334 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge after chemotherapy completion with close outpatient follow up
Number of subjects: 20
Study 21393334 — intervention group
Group type: COMPARATOR
Intervention: Inpatient control group
Number of subjects: 20
Study 21393393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced walk (SPW) after rehabilitation
Number of subjects: 50
Study 21393393 — intervention group
Group type: COMPARATOR
Intervention: Self-paced walk (SPW) before rehabilitation
Number of subjects: 50
Study 21394036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone
Number of subjects: 34
Study 21394036 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 120 mg with Amlodipine 10 mg
Number of subjects: 34
Study 21394036 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg alone
Number of subjects: 34
Study 21394036 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg with Fimasartan 120 mg
Number of subjects: 34
Study 21395631 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated cysteamine (mean dose 15.2 mg/kg/day) for 24 weeks
Number of subjects: 13
Study 21396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 28
Study 21396639 — intervention group
Group type: COMPARATOR
Intervention: Control group (without IBD)
Number of subjects: 28
Study 21396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ulcerative pan-colitis
Number of subjects: 28
Study 21396639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe clinical disease
Number of subjects: 28
Study 21396809 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supplemental oxygen therapy
Number of subjects: 1060
Study 21396809 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with oxygen use in non-hypoxemic patients
Number of subjects: 1060
Study 21396809 — intervention group
Group type: COMPARATOR
Intervention: Risk factors for hypoxemia
Number of subjects: 1060
Study 21397456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser anterior capsulotomy
Number of subjects: 0
Study 21397456 — intervention group
Group type: COMPARATOR
Intervention: Manual continuous curvilinear capsulorhexis (CCC)
Number of subjects: 0
Study 21398104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) metered-dose inhaler (MDI) 100/10 μg with integrated dose counter, used twice daily for 4 weeks
Number of subjects: 233
Study 21398104 — intervention group
Group type: COMPARATOR
Intervention: Counterstrip™, a manual counting method
Number of subjects: 233
Study 21398104 — intervention group
Group type: EXPERIMENTAL
Intervention: MF/F MDI with integrated dose counter
Number of subjects: 233
Study 21398284 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland dysfunction (Md)
Number of subjects: 0
Study 21398284 — intervention group
Group type: COMPARATOR
Intervention: Normal donors (Mn)
Number of subjects: 0
Study 21398296 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobacumab (1.2 mg/kg, given every 72 h)
Number of subjects: 18
Study 21398330 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 30
Study 21398392 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV, administered in a 3-dose regimen.
Number of subjects: 30
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination coverage for all vaccines part of the Expanded Program on Immunization (EPI)
Number of subjects: 765
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: All recommended vaccines received
Number of subjects: 765
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely vaccination for measles vaccine
Number of subjects: 765
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely vaccination for Bacillus Calmette-Guérin (BCG) vaccine
Number of subjects: 765
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines received within recommended time ranges
Number of subjects: 765
Study 21402043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation coverage
Number of subjects: 765
Study 21403014 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTCA)
Number of subjects: 169
Study 21403014 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 169
Study 21403127 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 157
Study 21403127 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for CD20(+) patients
Number of subjects: 157
Study 21403127 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) for CD20(-) patients
Number of subjects: 157
Study 21403127 — intervention group
Group type: COMPARATOR
Intervention: Comparison of relapse rates between CD20(+) and CD20(-) patients
Number of subjects: 157
Study 21403139 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute office blood pressure measurement (OBPM)
Number of subjects: 84
Study 21406077 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 plasma RNA in female HIV-1 infected partners
Number of subjects: 3354
Study 21406077 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count in female HIV-1 infected partners
Number of subjects: 3354